Clarity to present DISCO trial data at ASCO-GI 2026
Sydney, Australia 9 December 2025 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the acceptance of an abstract and poster on the Phase II DISCO trial (NCT04438304)1 data exploring 64Cu-SARTATE in patients with…